GC Cell Corporation (KOSDAQ:144510)

Market Cap	209.03B -30.6%
Revenue (ttm)	162.00B -5.0%
Net Income	-246.40B
EPS	-16,396.74
Shares Out	15.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,148
Open	14,350
Previous Close	14,600
Day's Range	13,860 - 14,770
52-Week Range	11,610 - 28,450
Beta	0.57
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 674
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2025, GC Cell's revenue was 165.52 billion, a decrease of -5.12% compared to the previous year's 174.45 billion. Losses were -272.86 billion, 269.2% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 12, 2026

Data Sources Report a data error